Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Diazoxide-resistant hyperinsulism (DRH) is form of congenital isolated hyperinsulism caused by an abnormal insulin production by B-cells in the pancreas that can be diffuse or focal and is characterized by an excessive/ uncontrolled insulin secretion (inappropriate for the level of glycemia), recurrent episodes of profound hypoglycemia and resistance to medical management with diazoxide.
No clinical trials have been registered for diazoxide-resistant hyperinsulinism.
3 publications have been identified in PubMed for diazoxide-resistant hyperinsulinism. Research spans Case Report / Case Series (67%) and Review / Meta-Analysis (33%).
Wong T (2026). [PMID: 41982675](https://pubmed.ncbi.nlm.nih.gov/41982675/). *Front Pharmacol*. [Review / Meta-Analysis]
Laaraje A (2025). [PMID: 41693194](https://pubmed.ncbi.nlm.nih.gov/41693194/). *Pediatr Endocrinol Diabetes Metab*. [Case Report / Case Series]
Sherin S (2024). [PMID: 39759686](https://pubmed.ncbi.nlm.nih.gov/39759686/). *Cureus*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 1:00 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center